Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

Core Viewpoint - Azitra, Inc. is advancing its clinical development of ATR04-484, a precision dermatology candidate aimed at treating EGFR inhibitor-associated rash, with plans to dose the first patient in a Phase 1/2 trial in the first half of 2025 [1][3]. Group 1: Clinical Trial Details - Azitra will present a poster on the Phase 1/2 clinical trial of ATR04-484 at the 28th Annual Meeting of the American Society of Gene and Cell Therapy, scheduled for May 15, 2025, in New Orleans, Louisiana [2]. - The presentation will be led by Mary Spellman, MD, Chief Medical Officer, highlighting the clinical development of ATR04-484 and the study design [2]. Group 2: Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on innovative therapies for precision dermatology, with its lead program ATR-12 targeting Netherton syndrome, a rare skin disease [3]. - The ATR-12 program includes a Phase 1b clinical trial in adult patients, while ATR-04 is designed for EGFR inhibitor-associated rash, which affects approximately 150,000 people in the U.S. [3]. - Azitra has received Fast Track designation from the FDA for the ATR-04 program and has an open IND for this indication [3]. Group 3: Technological Platform - Azitra's programs are developed from a proprietary platform of engineered proteins and topical live biotherapeutic products, which includes a microbial library of around 1,500 bacterial strains [3]. - The platform is enhanced by artificial intelligence and machine learning technologies that assist in analyzing and predicting drug-like molecules from the microbial library [3].